Literature DB >> 10064193

Ifosfamide/carboplatin/etoposide (ICE), an effective salvaging therapy for recurrent malignant non-Hodgkin lymphoma of childhood: a Pediatric Oncology Group phase II study.

F H Kung1, M B Harris, J P Krischer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10064193     DOI： 10.1002/(sici)1096-911x(199903)32:3<225::aid-mpo12>3.0.co;2-n

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN： 0098-1532


× No keyword cloud information.
  7 in total

1.  Efficacy of high-dose methotrexate, ifosfamide, etoposide and dexamethasone salvage therapy for recurrent or refractory childhood malignant lymphoma.

Authors:  J T Sandlund; C-H Pui; H Mahmoud; Y Zhou; E Lowe; S Kaste; L E Kun; M J Krasin; M Onciu; F G Behm; R C Ribeiro; B I Razzouk; S C Howard; M L Metzger; G A Hale; R Rencher; K Graham; M M Hudson
Journal:  Ann Oncol       Date:  2010-07-12       Impact factor: 32.976

2.  Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: A report from the FAB/LMB 96 study group.

Authors:  Mitchell Cairo; Anne Auperin; Sherrie L Perkins; Ross Pinkerton; Lauren Harrison; Stanton Goldman; Catherine Patte
Journal:  Br J Haematol       Date:  2018-07-09       Impact factor: 6.998

Review 3.  Management of Non-Hodgkin Lymphoma: ICMR Consensus Document.

Authors:  Nirav Thacker; Sameer Bakhshi; Girish Chinnaswamy; Tushar Vora; Maya Prasad; Deepak Bansal; Sandeep Agarwala; Gauri Kapoor; Venkatraman Radhakrishnan; Siddharth Laskar; Tanvir Kaur; G K Rath; Rupinder Singh Dhaliwal; Brijesh Arora
Journal:  Indian J Pediatr       Date:  2017-04-05       Impact factor: 1.967

4.  A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Authors:  Timothy C Griffin; Sheila Weitzman; Howard Weinstein; Myron Chang; Mitchell Cairo; Robert Hutchison; Bruce Shiramizu; Joseph Wiley; Deborah Woods; Margaret Barnich; Thomas G Gross
Journal:  Pediatr Blood Cancer       Date:  2009-02       Impact factor: 3.167

Review 5.  The combination of monoclonal antibodies and conventional chemotherapy for children with malignant lymphoma: Opportunities and challenges.

Authors:  John T Sandlund
Journal:  Pediatr Blood Cancer       Date:  2009-02       Impact factor: 3.167

6.  Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: a children's oncology group report.

Authors:  Tanya M Trippett; Cindy L Schwartz; R Paul Guillerman; Alan S Gamis; Sharon Gardner; Shirley Hogan; Wendy B London; Lu Chen; Pedro de Alarcon
Journal:  Pediatr Blood Cancer       Date:  2014-10-12       Impact factor: 3.167

7.  Clinical outcome of relapsed or refractory burkitt lymphoma and mature B-cell lymphoblastic leukemia in children and adolescents.

Authors:  Hyery Kim; Eun Sil Park; Soo Hyun Lee; Hong Hoe Koo; Hyo Sun Kim; Chuhl Joo Lyu; So Eun Jun; Young Tak Lim; Hee Jo Baek; Hoon Kook; Ji Won Lee; Hyoung Jin Kang; Kyung Duk Park; Hee Young Shin; Hyeo Seop Ahn
Journal:  Cancer Res Treat       Date:  2014-07-21       Impact factor: 4.679
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.